Experiments in social responsibility

Paul Herrling
Additional contact information
Paul Herrling: head of corporate research at Novartis International

Nature, 2006, vol. 439, issue 7074, 267-268

Abstract: Pursuing drugs for neglected diseases is not a traditional part of the pharmaceutical company portfolio. But Paul Herrling of Novartis finds that it brings welcome changes both within and outside the industry.

Date: 2006
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/439267a Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:439:y:2006:i:7074:d:10.1038_439267a

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/439267a

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().